These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From the guest editor: Triple-negative breast cancer. Hudis CA Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684 [No Abstract] [Full Text] [Related]
5. Are triple-negative and basal-like breast cancer synonymous? Rakha E; Ellis I; Reis-Filho J Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240 [No Abstract] [Full Text] [Related]
6. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717 [No Abstract] [Full Text] [Related]
7. Prognosis of patients with triple-negative breast cancer and brain metastasis. Venkitaraman R; Joseph T; Dhadda A; Chaturvedi A; Upadhyay S Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):729-30. PubMed ID: 19643588 [No Abstract] [Full Text] [Related]
8. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas. Frederik P; Cecile C; Tjalma WA Breast J; 2007; 13(4):436-7. PubMed ID: 17593058 [No Abstract] [Full Text] [Related]
9. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Venkitaraman R Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer. Sakamoto G; Honma N Breast Cancer; 2009; 16(4):281-2. PubMed ID: 19387776 [TBL] [Abstract][Full Text] [Related]
11. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
12. Pattern of metastatic spread in triple-negative breast cancer. Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer in focus: treatment options for triple-negative metastatic breast cancer. O'Shaughnessy JA Clin Adv Hematol Oncol; 2012 Jan; 10(1):43-5. PubMed ID: 22398807 [No Abstract] [Full Text] [Related]
14. Triple-negative breast cancer: role of the androgen receptor. Gucalp A; Traina TA Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692 [TBL] [Abstract][Full Text] [Related]
15. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. Mehta RS J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566 [No Abstract] [Full Text] [Related]
16. New approaches for triple-negative breast cancer. Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999 [No Abstract] [Full Text] [Related]
17. What is the difference between triple-negative and basal breast cancers? Seal MD; Chia SK Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685 [TBL] [Abstract][Full Text] [Related]
18. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Niwińska A; Pogoda K; Murawska M; Niwiński P Eur J Surg Oncol; 2011 Jul; 37(7):635-42. PubMed ID: 21664097 [TBL] [Abstract][Full Text] [Related]
19. Invasive papillary carcinoma of the breast: an overview of twenty-four cases. Vural O; Alnak A; Altundag K Am Surg; 2012 Mar; 78(3):E144-5. PubMed ID: 22524741 [No Abstract] [Full Text] [Related]
20. Triple negative breast cancer: breast cancer research in evolution. Eng-Wong J; Hunsberger S; Zujewski JA Breast Dis; 2010; 32(1-2):1-4. PubMed ID: 21778576 [No Abstract] [Full Text] [Related] [Next] [New Search]